SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S ...
- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term Milestones, plus Tiered Royalties - - 3D Medicines to Lead Clinical Development and Commercialization of GPS and GPS+ in Greater …